Article
Oncology
Natsuki Teruya, Hiroaki Inoue, Rie Horii, Futoshi Akiyama, Takayuki Ueno, Shinji Ohno, Shunji Takahashi
Summary: The study investigated the predictive and prognostic value of intratumoral heterogeneity and conventional clinicopathological factors in ER+HER2+ breast cancer. The results showed that the composition of tumor cells was associated with prognosis, and the combination of posttreatment Ki67 and complete pathological response could more accurately predict prognosis.
Article
Medicine, General & Internal
Saverio Coiro, Elisa Gasparini, Giuseppe Falco, Giacomo Santandrea, Moira Foroni, Giulia Besutti, Valentina Iotti, Roberto Di Cicilia, Monica Foroni, Simone Mele, Guglielmo Ferrari, Giancarlo Bisagni, Moira Ragazzi
Summary: The use of neoadjuvant chemotherapy for breast cancer is increasing, leading to changes in biomarkers such as ER, PR, Ki67, and HER2 status. These changes have prognostic implications across all intrinsic subtypes of breast cancer, particularly affecting therapy in HER2 negative and/or hormone receptor negative cases. Retesting biomarkers after NACT is crucial for improving tailored adjuvant therapies and patient prognosis.
Article
Health Care Sciences & Services
Fan Yang, Jiayi Li, Hong Zhang, Shuang Zhang, Jingming Ye, Yuanjia Cheng, Qian Liu, Ling Xin, Hongyu Xiang, Yinhua Liu, Xuening Duan, Ling Xu
Summary: This study retrospectively analyzed patients with early-stage luminal B breast cancer and found that low AR expression is associated with poor prognosis. High AR/ER and residual tumor Ki67 are associated with poor DFS in the neoadjuvant group.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Oncology
Jharna Datta, Natalie Willingham, Jasmine M. Manouchehri, Patrick Schnell, Mirisha Sheth, Joel J. David, Mahmoud Kassem, Tyler A. Wilson, Hanna S. Radomska, Christopher C. Coss, Chad E. Bennett, Ramesh K. Ganju, Sagar D. Sardesai, Maryam Lustberg, Bhuvaneswari Ramaswamy, Daniel G. Stover, Mathew A. Cherian
Summary: Highly selective ER beta agonists have been shown to effectively inhibit the viability of ER alpha+ breast cancer cell lines in vitro, suggesting a potential therapeutic strategy for ER alpha+ breast cancer. The combination of ER beta agonists with ER alpha antagonists shows strong synergy, maximizing the efficacy of ER beta agonists in blocking cell proliferation, migration, and inducing apoptosis. Negative correlation between ESR2 (ER beta gene) expression and ESR1 (ER alpha gene) and CCND1 RNA expression was observed in human metastatic ER alpha+/HER2- breast cancer samples.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Ho Tsoi, Wai-Chung Tsang, Ellen P. S. Man, Man-Hong Leung, Chan-Ping You, Sum-Yin Chan, Wing-Lok Chan, Ui-Soon Khoo
Summary: This study reveals that tamoxifen treatment can enhance the expression of BQ in ER-positive breast cancer by activating the ATM/CHK2 axis. Targeting CHK2 is a promising approach to overcoming tamoxifen resistance in ER-positive breast cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Anette H. Skjervold, Marit Valla, Anna M. Bofin
Summary: In this study, we examined the associations between levels of ER expression and tumour characteristics and prognosis in three large cohorts of BC patients. The results showed that ER Low Positive tumours were mainly found in Luminal B (HER2+) subtype and grade 3 tumours. The risk of death from BC was lower in ER Low Positive and ER ≥ 10% compared to ER-negative cases. Patients diagnosed in 1995 or later with ER Low Positive BCs had smaller, lower-grade tumours with lower proliferation status and similar prognosis compared to those with ER ≥ 10% tumours.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Cell Biology
Anastasia Alataki, Lila Zabaglo, Holly Tovey, Andrew Dodson, Mitch Dowsett
Summary: The study evaluated the use of the Cognition Master Professional Suite (CogM) image analysis software for Ki67 scoring in primary breast cancer samples. The results showed a high correlation between manual and digital scores, as well as no significant bias, demonstrating the reliability and accuracy of CogM in automated Ki67 scoring.
Article
Medicine, General & Internal
Rezvan Esmaeili, Samaneh Mohammadi, Narges Jafarbeik-Iravani, Fatemeh Yadegari, Asiieh Olfatbakhsh, Mahta Mazaheri, Ahmad Kaviani, Mahdi Rezaee, Keivan Majidzadeh-A
Summary: This study evaluated steroid biomarker genes in breast cancer patients and found associations between specific gene combinations and patient survival rates, providing important insights for breast cancer screening and treatment.
ARCHIVES OF IRANIAN MEDICINE
(2021)
Article
Oncology
Vikrant Mehta, Prabhat Suman, Harish Chander
Summary: This study aimed to analyze the expression of CHAC1 protein in malignant breast cancer tissues. The results showed significant up-regulation of CHAC1 in breast cancer tissues, and it was associated with high proliferation and positive lymph node metastasis. High CHAC1 expression was associated with poor overall survival in breast cancer patients, suggesting that CHAC1 may have a prognostic significance in breast cancer.
CLINICAL & TRANSLATIONAL ONCOLOGY
(2022)
Article
Oncology
Federica Miglietta, Gaia Griguolo, Michele Bottosso, Tommaso Giarratano, Marcello Lo Mele, Matteo Fassan, Matilde Cacciatore, Elisa Genovesi, Debora De Bartolo, Grazia Vernaci, Ottavia Amato, Francesca Porra, PierFranco Conte, Valentina Guarneri, Maria Vittoria Dieci
Summary: The expression of HER2-low-positive shows high instability from primary breast cancer to residual disease after neoadjuvant treatment. HER2-low-positive expression in residual disease may guide personalized adjuvant treatment for high-risk patients in clinical trials.
Article
Cell Biology
Torsten O. Nielsen, Samuel C. Y. Leung, Nazia Riaz, Anna M. Mulligan, Zuzana Kos, Anita Bane, Timothy J. Whelan
Summary: The LUMINA trial showed that in women aged 55 and above with low-risk luminal A breast cancer, very low local recurrence rate was observed when treated with breast-conserving surgery and endocrine therapy, supporting the safe omission of radiation. Ki67 is a practical, reproducible, and inexpensive biomarker that can identify low-risk luminal A breast cancers as potential candidates for radiation de-escalation.
Article
Oncology
Veronica C. Shim, Robin J. Baker, Wen Jing, Roisin Puentes, Sally S. Agersborg, Thomas K. Lee, Wamda Goreai, Ninah Achacoso, Catherine Lee, Marvella Villasenor, Amy Lin, Malathy Kapali, Laurel A. Habel
Summary: The International Ki67 Working Group has developed a training program for improving the reproducibility of immunohistochemistry scoring and recommends specific cut points for prognosis in ER+, HER2-, stage I/II breast cancer. The overlap between these cut points and the Recurrence Score (RS) assay remains moderate, indicating the unclear clinical utility of using these cut points for further testing.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Review
Endocrinology & Metabolism
Ailin Zhang, Xiaojing Wang, Chuifeng Fan, Xiaoyun Mao
Summary: Ki67, a proliferation marker, is proposed for breast cancer subtype classification, prognosis, and therapeutic response prediction. However, its questionable analytical validity hinders its widespread adoption in treatment decisions for breast cancer. Studies have shown potential for Ki67 as a predictive marker in neoadjuvant endocrine therapy.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Oncology
Lili Chen, Yanyang Chen, Zhongpeng Xie, Jiao Luo, Yuefeng Wang, Jianwen Zhou, Leilei Huang, Hongxia Li, Linhai Wang, Pei Liu, Man Shu, Wenhui Zhang, Zunfu Ke
Summary: The concordance between RT-qPCR and IHC for assessment of breast cancer subtypes was evaluated, and RT-qPCR was found to be a supplementary method for detecting molecular markers of breast cancer.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Review
Biochemistry & Molecular Biology
Erin R. Scheidemann, Ayesha N. Shajahan-Haq
Summary: ER+ breast cancer is the most common form, with resistance to antiestrogens leading to the development of CDK4/6 inhibitors as a successful alternative treatment option. However, resistance to these inhibitors is also common, with various mechanisms identified. Future research should focus on developing biomarkers to guide treatment strategies for resistant patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Vaidehi Jobanputra, Kazimierz O. Wrzeszczynski, Reinhard Buttner, Carlos Caldas, Edwin Cuppen, Sean Grimmond, Torsten Haferlach, Charles Mullighan, Anna Schuh, Olivier Elemento
Summary: Whole-genome and transcriptome sequencing (WGTS) provides new opportunities for identifying and reporting a larger number of potentially actionable alterations in clinical tumor samples. However, these comprehensive tests also come with challenges such as the extent and diversity of sequence alterations and the complexity of interpretation.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Oncology
Manja Meggendorfer, Vaidehi Jobanputra, Kazimierz O. Wrzeszczynski, Paul Roepman, Ewart de Bruijn, Edwin Cuppen, Reinhard Buttner, Carlos Caldas, Sean Grimmond, Charles G. Mullighan, Olivier Elemento, Richard Rosenquist, Anna Schuh, Torsten Haferlach
Summary: Interrogating the tumor genome through whole-genome sequencing (WGS) has the potential to impact cancer diagnostics, prognostication, and therapy selection. This review emphasizes the requirements for implementing, validating, and maintaining a clinical WGS pipeline to obtain high-quality patient-specific data.
SEMINARS IN CANCER BIOLOGY
(2022)
Review
Oncology
Richard Rosenquist, Edwin Cuppen, Reinhard Buettner, Carlos Caldas, Helene Dreau, Olivier Elemento, Geert Frederix, Sean Grimmond, Torsten Haferlach, Vaidehi Jobanputra, Manja Meggendorfer, Charles G. Mullighan, Sarah Wordsworth, Anna Schuh
Summary: Precision diagnostics is an important aspect of precision medicine, and whole-genome sequencing can be used to predict and respond to cancer treatment. National initiatives aim to introduce clinical whole-genome sequencing as a rational and effective diagnostic tool, but there is a lack of systematic evaluation of the clinical utility of whole-genome sequencing.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Oncology
Tom van den Bosch, Oscar M. Rueda, Carlos Caldas, Louis Vermeulen, Daniel M. Miedema
Summary: This study found that low-risk breast cancer patients identified using chromosomal copy-number ITH do not benefit from adjuvant endocrine therapy.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Xiaoyu Wang, Puya Gharahkhani, David M. Levine, Rebecca C. Fitzgerald, Ines Gockel, Douglas A. Corley, Harvey A. Risch, Leslie Bernstein, Wong-Ho Chow, Lynn Onstad, Nicholas J. Shaheen, Jesper Lagergren, Laura J. Hardie, Anna H. Wu, Paul D. P. Pharoah, Geoffrey Liu, Lesley A. Anderson, Prasad G. Iyer, Marilie D. Gammon, Carlos Caldas, Weimin Ye, Hugh Barr, Paul Moayyedi, Rebecca Harrison, R. G. Peter Watson, Stephen Attwood, Laura Chegwidden, Sharon B. Love, David MacDonald, John DeCaestecker, Hans Prenen, Katja Ott, Susanne Moebus, Marino Venerito, Hauke Lang, Rupert Mayershofer, Michael Knapp, Lothar Veits, Christian Gerges, Josef Weismueller, Matthias Reeh, Markus M. Noethen, Jakob R. Izbicki, Hendrik Manner, Horst Neuhaus, Thomas Roesch, Anne C. Boehmer, Arnulf H. Hoelscher, Mario Anders, Oliver Pech, Brigitte Schumacher, Claudia Schmidt, Thomas Schmidt, Tania Noder, Dietmar Lorenz, Michael Vieth, Andrea May, Timo Hess, Nicole Kreuser, Jessica Becker, Christian Ell, Ian Tomlinson, Claire Palles, Janusz A. Jankowski, David C. Whiteman, Stuart MacGregor, Johannes Schumacher, Thomas L. Vaughan, Matthew F. Buas, James Y. Dai
Summary: This study identified novel genetic susceptibility loci for esophageal adenocarcinoma and Barrett esophagus using an eQTL set-based genetic association approach, expanding the pool of genetic susceptibility loci.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Oncology
Violeta Serra, Anderson T. Wang, Marta Castroviejo-Bermejo, Urszula M. Polanska, Marta Palafox, Andrea Herencia-Ropero, Gemma N. Jones, Zhongwu Lai, Joshua Armenia, Filippos Michopoulos, Alba Llop-Guevara, Rachel Brough, Aditi Gulati, Stephen J. Pettitt, Krishna C. Bulusu, Jenni Nikkila, Zena Wilson, Adina Hughes, Paul W. G. Wijnhoven, Ambar Ahmed, Alejandra Bruna, Albert Gris-Oliver, Marta Guzman, Olga Rodriguez, Judit Grueso, Joaquin Arribas, Javier Cortes, Cristina Saura, Alan Lau, Susan Critchlow, Brian Dougherty, Carlos Caldas, Gordon B. Mills, J. Carl Barrett, Josep V. Forment, Elaine Cadogan, Christopher J. Lord, Cristina Cruz, Judith Balmana, Mark J. O'Connor
Summary: Targeting the replication stress response is a valid therapeutic option to overcome PARPi resistance, providing new strategies for treating tumors such as breast and ovarian cancer.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Lizelle Correia, Ramiro Magno, Joana M. Xavier, Bernardo P. de Almeida, Isabel Duarte, Filipa Esteves, Marinella Ghezzo, Matthew Eldridge, Chong Sun, Astrid Bosma, Lorenza Mittempergher, Ana Marreiros, Rene Bernards, Carlos Caldas, Suet-Feung Chin, Ana-Teresa Maia
Summary: PIK3CA mutations are common in breast cancer, and there is an allelic expression imbalance between the mutant and wild-type alleles. Preferential expression of the mutant allele is associated with poor prognosis, and ER-, PR-, and HER2+ tumors show significant preferential expression of the mutant allele.
Article
Oncology
Filipa Esteves, Joana M. Xavier, Anthony M. Ford, Catia Rocha, Paul D. P. Pharoah, Carlos Caldas, Suet-Feung Chin, Ana-Teresa Maia
Summary: This study introduces a novel approach using allelic expression ratios to identify risk associations, causal regulatory variants, and target genes in GWAS. By measuring AE ratios in normal breast tissue and blood samples, and conducting in-silico and in-vitro analysis, the study identifies putative causal variants and target genes for the 17q22 breast cancer risk locus.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Multidisciplinary Sciences
Filipe Correia Martins, Dominique-Laurent Couturier, Ines de Santiago, Carolin Margarethe Sauer, Maria Vias, Mihaela Angelova, Deborah Sanders, Anna Piskorz, James Hall, Karen Hosking, Anumithra Amirthanayagam, Sabina Cosulich, Larissa Carnevalli, Barry Davies, Thomas B. K. Watkins, Ionut G. Funingana, Helen Bolton, Krishnayan Haldar, John Latimer, Peter Baldwin, Robin Crawford, Matthew Eldridge, Bristi Basu, Mercedes Jimenez-Linan, Andrew W. Mcpherson, Nicholas McGranahan, Kevin Litchfield, Sohrab P. Shah, Iain McNeish, Carlos Caldas, Gerard Evan, Charles Swanton, James D. Brenton
Summary: Identification of clonal somatic copy number alterations in cancer genes can guide precision medicine for high-grade serous ovarian carcinoma.
NATURE COMMUNICATIONS
(2022)
Article
Multidisciplinary Sciences
Ha-Linh Nguyen, Tatjana Geukens, Marion Maetens, Samuel Aparicio, Ayse Bassez, Ake Borg, Jane Brock, Annegien Broeks, Carlos Caldas, Fatima Cardoso, Maxim De Schepper, Mauro Delorenzi, Caroline A. Drukker, Annuska M. Glas, Andrew R. Green, Edoardo Isnaldi, Jorunn Eyfjoro, Hazem Khout, Stian Knappskog, Savitri Krishnamurthy, Sunil R. Lakhani, Anita Langerod, John W. M. Martens, Amy E. McCart Reed, Leigh Murphy, Stefan Naulaerts, Serena Nik-Zainal, Ines Nevelsteen, Patrick Neven, Martine Piccart, Coralie Poncet, Kevin Punie, Colin Purdie, Emad A. Rakha, Andrea Richardson, Emiel Rutgers, Anne Vincent-Salomon, Peter T. Simpson, Marjanka K. Schmidt, Christos Sotiriou, Paul N. Span, Kiat Tee Benita Tan, Alastair Thompson, Stefania Tommasi, Karen Van Baelen, Marc Van de Vijver, Steven Van Laere, Laura van't Veer, Giuseppe Viale, Alain Viari, Hanne Vos, Anke T. Witteveen, Hans Wildiers, Giuseppe Floris, Abhishek D. Garg, Ann Smeets, Diether Lambrechts, Elia Biganzoli, Francois Richard, Christine Desmedt
Summary: Obesity is associated with an increased risk of developing breast cancer and worse prognosis in breast cancer patients. This study investigates the biological differences in untreated primary breast cancer according to patients' body mass index (BMI). The study finds several genomic alterations that are differentially prevalent in overweight or obese patients compared to lean patients. It also reveals an elevated and unresolved inflammation of the breast cancer tumor microenvironment associated with obesity. The findings suggest that patient adiposity may play a significant role in the heterogeneity of breast cancer and should be considered for tailored treatment.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Edwin Cuppen, Olivier Elemento, Richard Rosenquist, Svetlana Nikic, Maarten IJzerman, Isabelle Durand Zaleski, Geert Frederix, Lars-Ake Levin, Charles G. Mullighan, Reinhard Buettner, Trevor J. Pugh, Sean Grimmond, Carlos Caldas, Fabrice Andre, Ilse Custers, Elias Campo, Hans van Snellenberg, Anna Schuh, Hidewaki Nakagawa, Christof von Kalle, Torsten Haferlach, Stefan Froehling, Vaidehi Jobanputra
Summary: The combination of whole-genome and transcriptome sequencing (WGTS) is a comprehensive precision diagnostic test that is expected to transform diagnosis and treatment for cancer patients. However, there are barriers to the implementation and widespread adoption of this test, including considerations of utility in different cancer types, cost-effectiveness and affordability.
JCO PRECISION ONCOLOGY
(2022)
Review
Oncology
Emily A. Kolyvas, Carlos Caldas, Kathleen Kelly, Saif S. Ahmad
Summary: Breast cancer is a common and deadly cancer, and the role of AR in this type of cancer is still not fully understood. However, targeting AR in breast cancer may have therapeutic potential and further research is needed for effective treatment.
BREAST CANCER RESEARCH
(2022)
Correction
Oncology
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Adria Lopez-Fernandez, Markus Jonsson, Ali Razzak, Irene Brana, Luigi De Petris, Jeffrey Yachnin, Richard D. Baird, Yohann Loriot, Christophe Massard, Patricia Martin-Romano, Frans Opdam, Richard F. Schlenk, Claudio Vernieri, Michele Masucci, Xenia Villalobos, Elena Chavarria, Judith Balmana, Giovanni Apolone, Carlos Caldas, Jonas Bergh, Ingemar Ernberg, Stefan Frohling, Elena Garralda, Claes Karlsson, Josep Tabernero, Emile Voest, Jordi Rodon, Janne Lehtio
Article
Oncology
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Adria Lopez-Fernandez, Markus Jonsson, Ali Razzak, Irene Brana, Luigi De Petris, Jeffrey Yachnin, Richard D. Baird, Yohann Loriot, Christophe Massard, Patricia Martin-Romano, Frans Opdam, Richard F. Schlenk, Claudio Vernieri, Michele Masucci, Xenia Villalobos, Elena Chavarria, Judith Balmana, Giovanni Apolone, Carlos Caldas, Jonas Bergh, Ingemar Ernberg, Stefan Frohling, Elena Garralda, Claes Karlsson, Josep Tabernero, Emile Voest, Jordi Rodon, Janne Lehtio
Summary: This article presents the implementation of the Molecular Tumor Board Portal, a system that integrates and interprets genomics and clinical data to support clinical decision-making in precision oncology. The system automates the interpretation and reporting of sequencing results, reducing errors and promoting consistent decision-making and data capture. It also facilitates collaborative discussion through information-rich patient reports and interactive content.
Article
Multidisciplinary Sciences
Stephen-John Sammut, Mireia Crispin-Ortuzar, Suet-Feung Chin, Elena Provenzano, Helen A. Bardwell, Wenxin Ma, Wei Cope, Ali Dariush, Sarah-Jane Dawson, Jean E. Abraham, Janet Dunn, Louise Hiller, Jeremy Thomas, David A. Cameron, John M. S. Bartlett, Larry Hayward, Paul D. Pharoah, Florian Markowetz, Oscar M. Rueda, Helena M. Earl, Carlos Caldas
Summary: The response to therapy in breast cancers is influenced by the pre-treated tumour ecosystem, and predictive models integrating multi-omics features through machine learning can be used to predict treatment outcomes. The degree of residual disease following therapy is monotonically associated with pre-therapy features of the tumour.